B Livarek

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Peripheral artery occlusive disease (PAOD) is an emerging adverse event in chronic myelogenous leukemia (CML) patients treated with nilotinib. 1–4 The largest published cohort of CML patients treated with nilotinib comes from the phase III ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-newly diagnosed patients), which compared(More)
  • 1